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A rheostat mechanism governs the bifurcation
of carbon ﬂux in mycobacteria
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Fatty acid metabolism is an important feature of the pathogenicity of Mycobacterium
tuberculosis during infection. Consumption of fatty acids requires regulation of carbon ﬂux
bifurcation between the oxidative TCA cycle and the glyoxylate shunt. In Escherichia coli, ﬂux
bifurcation is regulated by phosphorylation-mediated inhibition of isocitrate dehydrogenase
(ICD), a paradigmatic example of post-translational mechanisms governing metabolic ﬂuxes.
Here, we demonstrate that, in contrast to E. coli, carbon ﬂux bifurcation in mycobacteria is
regulated not by phosphorylation but through metabolic cross-activation of ICD by
glyoxylate, which is produced by the glyoxylate shunt enzyme isocitrate lyase (ICL). This
regulatory circuit maintains stable partitioning of ﬂuxes, thus ensuring a balance between
anaplerosis, energy production, and precursor biosynthesis. The rheostat-like mechanism of
metabolite-mediated control of ﬂux partitioning demonstrates the importance of allosteric
regulation during metabolic steady-state. The sensitivity of this regulatory mechanism to
perturbations presents a potentially attractive target for chemotherapy.
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T
uberculosis (TB), caused by Mycobacterium tuberculosis,
shares with HIV and malaria the distinction of being one
of the deadliest infectious diseases of our time. Lipids and
fatty acids are thought to serve as important sources of carbon
and energy forM. tuberculosis during infection1,2. The dual use of
these substrates places a premium on metabolic regulatory
mechanisms to ensure a balance between metabolite oxidation
for energy gain and metabolite conservation for biomass
production.
Intermediates of the tricarboxylic acid (TCA) cycle that are
diverted into biosynthetic pathways must be replenished by
anaplerotic reactions. During growth on glycolytic substrates,
anaplerosis involves transformation of glycolytic intermediates
(C3-units) into TCA cycle intermediates (C4-units). These ﬂuxes
are absent during growth on fatty acids, which enter central
carbon metabolism mainly as acetyl-CoA (C2-units). Instead, a
fraction of the TCA cycle intermediate isocitrate is diverted into
the glyoxylate shunt, bypassing the oxidative decarboxylation
steps in the TCA cycle and replenishing intermediates that are
used for biosynthesis of cellular constituents3. Since both
pathways are essential under these conditions—the glyxoylate
shunt for anaplerosis, the oxidative TCA cycle for energy and
biosynthetic precursors—balancing the ﬂux ratio at the
bifurcation of these pathways is critical4. In enteric bacteria,
the glyoxylate shunt is activated by transcriptional induction of
the catabolite-repressed genes encoding isocitrate lyase (ICL) and
malate synthase (MLS). After such transcriptional activation, the
ﬂux ratio between the oxidative TCA cycle and the glyoxylate
shunt is controlled by post-translational regulation mediated by
reversible phosphorylation5–7. This regulation is achieved by
partial inactivation of isocitrate dehydrogenase (ICD), which
competes with ICL for their shared substrate (isocitrate)8. The
bifunctional enzyme AceK catalyzes both the phosphorylation
and dephosphorylation of ICD to render the enzyme inactive and
active, respectively8,9.
In contrast to E. coli, the molecular mechanisms that control
partitioning of carbon ﬂuxes between the TCA cycle and
glyoxylate shunt are not understood in mycobacteria, despite
the important role of ﬂux bifurcation in M. tuberculosis
pathogenicity10,11. Here, we report that phosphorylation of ICD
does not play a role in controlling the bifurcation of isocitrate
ﬂuxes between the TCA cycle and glyoxylate shunt in
M. smegmatis, which encodes only one ICD. In M. tuberculosis
and M. bovis BCG, which encode two ICD isoforms12,13, we
demonstrate that only ICD2 (homologue of ICD in
M. smegmatis) has an important physiological role under the
tested growth conditions. In the absence of ICD phosphorylation,
we present evidence that ﬂux partitioning between the TCA cycle
and the glyoxylate shunt is mediated by cross-activation of ICD
by glyoxylate produced by ICL.
Results
ICD2 is exclusively required for oxidative TCA cycle ﬂux.
M. tuberculosis andM. bovis BCG encode two distinct isoforms of
ICD: ICD1 (409 AA) and ICD2 (745 AA). The M. smegmatis
genome encodes a single ICD (743 AA), a homologue of ICD2 in
M. tuberculosis and M. bovis BCG. Both isoenzymes (ICD1 and
ICD2) are biochemically active in vitro14. To study the relative
contributions of the isoenzymes to oxidative TCA cycle ﬂuxes
in vivo, we generated gene deletion strains. ICD activity is
undetectable in ICD2-deﬁcient M. smegmatis and ICD2-deﬁcient
M. bovis BCG but is indistinguishable from wild-type in ICD1-
deﬁcient M. bovis BCG (Table 1; Supplementary Table 1). An
ICD2-deﬁcient strain of M. smegmatis cultured in Middlebrook
7H9 medium shows a late growth phenotype that coincides with
depletion of glutamate from the culture medium (Fig. 1a).
Glutamate auxotrophy of the ICD2-deﬁcient strain was
conﬁrmed by demonstrating that ICD2 is required for growth
on minimal medium lacking glutamate (Fig. 1b; Supplementary
Fig. 1). Incubation of ICD2-deﬁcient bacteria in minimal medium
without glutamate supplementation leads to decreased levels of
metabolites downstream of ICD (a-ketoglutarate and glutamate)
(Fig. 1c). In addition, loss of ICD2 increases the levels of
metabolites upstream of ICD (citrate/isocitrate) compared with
wild-type and complemented bacteria cultivated in media devoid
of glutamic acid (Fig. 1c), as expected upon perturbation of a
metabolic enzyme15. In M. bovis BCG, deletion of icd2 results in
glutamate auxotrophy, whereas deletion of icd1 has no effect
(Fig. 1d; Supplementary Table 1), and glutamate prototrophy is
restored by complementation of the Dicd2 strain with a plasmid
encoding icd2 (Fig. 1e). ICD2-deﬁcient M. smegmatis and
M. bovis BCG lose viability over time when incubated in
medium without glutamate supplementation, suggesting that
energy metabolism or production of biosynthetic intermediates
through the oxidative TCA cycle is essential for survival under
these conditions (Fig. 1f,g).
We conclude that under the conditions tested ICD2 is
responsible for carbon ﬂux through the oxidative TCA cycle in
both M. smegmatis and M. bovis BCG, whereas the physiological
role of ICD1 in M. bovis BCG is currently unclear. Multiple
attempts to delete the icd2 gene in M. tuberculosis were
unsuccessful, consistent with whole-genome mutagenesis studies
suggesting that icd2 might be essential in M. tuberculosis16.
3D structure of MsmICD does not support phospho-regulation.
A structural survey of bacterial ICDs revealed that only ICDs
from Gram-negative bacteria are likely to be targets for the
bifunctional kinase-phosphatase AceK17. However, by analogy to
AceK, the mono-functional serine–threonine protein kinase G
(PknG) in mycobacteria has been proposed to regulate ﬂuxes
Table 1 | ICD activity in cell-free extracts of bacteria grown on glucose or acetate.
Bacterial strain ICD activity* Glucose (Glc) ICD activity* Acetate (Ace) Ratio (Glc/Ace)
M. bovis BCG 0.65±0.09 1.01±0.14 0.64
BCG Dicd1 0.63±0.08 1.12±0.13 0.56
BCG Dicd2 NDw NDw
BCG Dicd2 attB::Pnpicd2z 1.55±0.06 2.91±0.83 0.53
M. smegmatis 0.84±0.24 2.08±0.13 0.40
M. smegmatis Dicd2 0.01±0.01 0.02±0.01 0.50
M. smegmatis Dicd attB::Pnpicdw 1.02±0.18 3.19±0.42 0.32
Data are means±s.d. (nZ3 independent experiments each performed in triplicate).
*ICD speciﬁc activity in cell-free extracts (U mg 1).
wNot detectable.
zStrain complemented with single-copy pMV306-based plasmids integrated at the chromosomal attB site. In each case, the complementing gene is expressed from the native promoter (Pnp).
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Figure 1 | Loss of ICD2 results in glutamate auxotrophy and impaired viability. (a) Growth (OD600) of wild-type, Dicd and Dicd attB::Pnpicd-complemented
strains of M. smegmatis in Middlebrook 7H9 medium. Solid lines, culture density (OD600). Dashed lines, glutamate concentration in culture medium. (b) Growth
(OD600) of wild-type, Dicd and Dicd attB::Pnpicd-complemented strains of M. smegmatis in minimal medium supplemented with glucose and devoid of glutamate.
Data are means±s.d. (n¼ 3 independent experiments). (c) Intracellular metabolites in wild-type, Dicd and Dicd attB::Pnpicd-complemented strains of M. smegmatis
24h after transferring cells into minimal medium supplemented with glucose and devoid of glutamate. Data are means±s.d. (n¼ 3 independent experiments).
CIT/ICT, citrate/isocitrate; a-KG, alpha-ketoglutarate; GLU, glutamate. (d,e) Growth (OD600) of wild-type, Dicd1, Dicd2 and Dicd2 attB::Pnpicd2-complemented
strains of M. bovis BCG in minimal medium supplemented with glucose and glutamate (d) or without glutamate (e). (f) Survival (CFU) of wild-type, Dicd and Dicd
attB::Pnpicd-complemented strains of M. smegmatis in minimal medium supplemented with glucose and devoid of glutamate. Data are means±s.d. (n¼ 3
independent experiments each performed in triplicate). (g) Survival (CFU) of wild-type, Dicd2 and Dicd2 attB::Pnpicd2-complemented strains of M. bovis BCG in
minimal medium supplemented with glucose and devoid of glutamate. Data are means±s.d. (n¼ 3 independent experiments each performed in triplicate).
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through the TCA cycle by phosphorylation-mediated inactivation
of ICD18,19. We used X-ray crystallography to solve the three-
dimensional (3D) structure of M. smegmatis ICD (MsmICD) to
evaluate whether it might support a phospho-regulatory
mechanism. We determined the structure of MsmICD bound to
isocitrate and manganese to a resolution of 2.8 Å using molecular
replacement with ICD of Azotobacter vinelandii (AvICD) as
template (Supplementary Table 2). MsmICD, the homologue of
M. tuberculosis ICD2, is similar to the NADPþ -dependent ICD
of Corynebacterium glutamicum (CgICD) with a sequence
identity of 59% and an rmsd of 3.9 Å of all C-alpha atoms
(DaliLite v.3). The tertiary structure of MsmICD (PDB: 4ZDA)
consists of two distinct domains, similar to the ICD structures of
AvICD and CgICD (Fig. 2a). A cleft region between the two
domains contains the active site, as described for other ICD
enzymes20,21.
The phospho-regulatory P-loop of E. coli ICD (EcICD),
comprising amino acid residues 94–113, includes a glycine-rich
motif forming a highly ﬂexible structure (Fig. 2c). In contrast, the
equivalent amino acid residues in MsmICD are more structured,
forming a short a-helix (amino acid residues 119–134) (Fig. 2d)
similar to the short a-helix loop in CgICD and AvICD
(Fig. 2b)20,21. Overlaid with EcICD, this short a-helix limits
access to the active site and would sterically hinder binding of
AceK to the AceK recognition sequence (ARS) (Fig. 2e). In
contrast to the EcICD ARS elements, which form a b-sheet
(Fig. 2c), the corresponding structural elements of MsmICD
resemble a Class-B ICD (Fig. 2d)17. Structural comparison of
representative ICD structures from enterobacteria that encode an
AceK homologue reveals remarkable sequence conservation in
their ARS elements compared with MsmICD and CgICD
(Supplementary Fig. 2). Indeed an AceK–EcICD complex
structure illustrates a highly speciﬁc recognition and intimate
interaction between the enzyme and the kinase, similar to several
documented cases in eukaryotic protein kinases9. The
discontinuous regions on EcICD that interact with AceK are:
the P-loop from domain (I) and the twisted antiparallel beta-sheet
(ARS) from domain (II). Notably, modiﬁcation of these
recognition sites on EcICD, analogous to the amino acid
residue differences in MsmICD, signiﬁcantly impairs the ability
of AceK to interact with EcICD9,22. Consistent with the genetic
and biochemical evidence presented hereafter, the structure of
MsmICD argues against a phosphorylation-mediated mechanism
for ICD regulation in mycobacteria.
PknG kinase does not regulate ICD activity. To further clarify
whether PknG contributes to the regulation of ICD activity, we
constructed PknG null strains and measured their growth kinetics
and ICD speciﬁc activity in carbon-deﬁned media. Although
deletion of AceK increases ICD activity by several-fold in E. coli,
PknG deﬁciency has no impact on ICD activity in mycobacteria
Domain I
Domain II
CgICD
AvlCD
MsmICD
Ser 134
Short helix
Class A ICD: EclCD
Ser 113
P-loop
ARS elements
Class B ICD: MsmlCD Overlay: MsmlCD & EcICD
a b
c d e
Figure 2 | Three-dimensional structure of M. smegmatis ICD (MsmICD). (a) Schematic of two deﬁned domains of MsmICD: a large domain (domain II)
and a small domain (domain I). The corresponding ‘P-loop domain’ is coloured in red, with Serine 134 depicted as a stick. The corresponding ‘ARS domain’
is coloured in green. The substrate isocitrate and cofactor Mn2þ are depicted as sticks in the active site. (b) Overlay of the alpha-helical P-loops of
MsmICD (red, this study), AvICD (yellow, PDB: 1ITW) and CgICD (green, PDB: 2B0T). (c) Class-A ICD of E. coli. Serine 113 extending from the ﬂexible
P-loop is depicted as a stick. (d) Class-B ICD of M. smegmatis. Unlike EcICD (PDB: 3LCB), which has a random coil P-loop and short ARS domain, MsmICD
has a corresponding rigid alpha-helical structure and an elongated ‘ARS domain’, which could sterically hinder the association of MsmICD with a regulatory
kinase. (e) Overlay of EcICD and MsmICD illustrates the differences between the two proteins in the key regions that mediate interaction of EcICD with
AceK.
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(Table 2). Furthermore, we found that PknG is dispensable for
growth of mycobacteria on acetate (Fig. 3c; Supplementary
Fig. 3), whereas AceK is essential for growth of E. coli on acetate
(Fig. 3a,b; Supplementary Movie 1). These observations suggest
that PknG is not involved in modulating ICD activity during
growth of mycobacteria on acetate. This conclusion is further
Table 2 | ICD activity in cell-free extracts of bacteria grown on glucose or acetate.
Bacterial strain ICD activity* Glucose (Glc) ICD activity* Acetate (Ace) Ratio (Glc/Ace)
M. tuberculosis Erdman 0.41±0.10 0.69±0.09 0.60
M. tuberculosis Erdman DpknG 0.46±0.14 0.62±0.03 0.75
M. tuberculosis H37Rv 0.42±0.04 0.63±0.08 0.66
M. tuberculosis CDC1551 0.35±0.03 0.58±0.06 0.61
M. tuberculosis HN787 0.44±0.08 0.62±0.03 0.72
M. bovis BCG 0.87±0.14 1.21±0.03 0.72
M. smegmatis 0.74±0.19 1.90±0.24 0.39
M. smegmatis DpknG 0.71±0.21 1.36±0.06 0.52
E. coli 1.25±0.21 0.35±0.06 3.58
E. coli DaceK 1.09±0.14 1.18±0.08 0.93
Data are means±s.d. (nZ3 independent experiments each performed in triplicate).
*ICD speciﬁc activity in cell-free extracts (U mg 1).
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Figure 3 | Phosphorylation-mediated branch-point regulation. (a) Growth (OD600) of wild-type and DaceK strains of E. coli on minimal medium
containing glucose (left) or acetate (right). Data are means±s.d. (n¼ 3 independent experiments). (b) Time-lapse series of GFP-expressing E. coli DaceK
cells grown in a microﬂuidic device and imaged on phase-contrast and ﬂuorescence channels (merged) at 5-minute intervals. Flow medium was
M9 minimal medium containing glucose (0–6 h) before switching to acetate (6–18 h) and then back to glucose (18–24 h). Scale bar, 3mm. (c) Growth
(OD600) of wild-type and DpknG strains of M. smegmatis (left) or M. tuberculosis (right) on minimal medium containing acetate. Data are means±s.d.
(n¼ 3 independent experiments).
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supported by the fact that immunoprecipitated ICD fractions
from glucose-grown and acetate-grown cells show indis-
tinguishable speciﬁc activity (0.85±0.21 and 0.87±0.18U mg 1,
respectively).
Bifurcation of ﬂuxes at the TCA cycle branch-point. Bacteria
growing on C2-carbon sources use the glyoxylate shunt for
anaplerosis of the TCA cycle while maintaining oxidative TCA
cycle activity for the production of energy and a-ketoglutarate-
related biomass precursors. In the absence of phosphorylation-
mediated modulation of ICD activity, we evaluated whether
partitioning of ﬂuxes between the TCA cycle and the glyoxylate
shunt occurs in mycobacteria. We used dynamic 13C-tracing to
estimate the ﬂux ratio between the two competing pathways23.
The conversion of isocitrate to succinate is either through the
oxidative branch of the TCA cycle or through the glyoxylate
shunt. Since both pathways conserve the two carbon atoms of
acetyl-CoA, the initial dynamics of the Mþ 2 mass isomer of
succinate (before extensive reshufﬂing of labelled carbons) after
shifting cells from unlabelled acetate to [U-13C]-acetate are
informative to determine the relative contributions of the two
converging metabolic ﬂuxes (Fig. 4a,b). Shifting cells from
unlabelled glucose to [U-13C]-glucose resulted in similar
dynamics of the Mþ 2 isomer fraction of a-ketoglutarate and
succinate over the ﬁrst 320 s that were comparable between wild-
type (Fig. 4c) and ICL-deﬁcient (Dicl1 Dicl2) (Fig. 4d) strains.
These results demonstrate that ﬂuxes through the glyoxylate
shunt are negligible in glucose-grown cells. In contrast, shifting
acetate-grown cells to [U-13C]-acetate resulted in a twofold faster
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Figure 4 | Bifurcation of metabolic ﬂuxes. (a) Schematic of ﬂuxes into the TCA cycle and glyoxylate shunt following shift from glucose (blue shading) to
radiolabelled acetate (red shading). (b) Schematic of ﬂuxes into the TCA cycle and glyoxylate shunt following shift from acetate (red shading) to
radiolabelled glucose (blue shading). (c,d) 13C-labelling of metabolites in wild-type (c) and Dicl1 Dicl2 (d) M. smegmatis 320 s after shifting glucose to
[U-13C]-glucose. Comparison of the Mþ 2 isomers of isocitrate, a-ketoglutarate and succinate demonstrate absence of carbon ﬂux through the glyoxylate
shunt during growth on glucose. (e) 13C-labelling of metabolites in wild-type M. smegmatis 80 s after shifting from acetate to [U-13C]-acetate illustrate
carbon ﬂux bifurcation to the glyoxylate shunt and the oxidative TCA cycle.
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Mþ 2 isomer accumulation for succinate compared with a-
ketoglutarate during the ﬁrst 80 s, which demonstrates substantial
ﬂux through the glyoxylate shunt (Fig. 4e). Isotopomer balancing,
assuming pseudo-steady-state labelling after 80 s, indicated that
32–38% of the succinate molecules are generated through the
glyoxylate shunt and 62–68% are generated through the oxidative
TCA cycle during growth on acetate. This is comparable to the
determined 1:2 to 1:3 ratio of ﬂuxes between the glyoxylate shunt
and the oxidative TCA cycle for acetate-grown E. coli and
C. glutamicum, respectively 4,24. Thus, the emerging picture of
mycobacterial metabolism is of exclusive utilization of the TCA
cycle during growth on glucose and bifurcation of ﬂuxes between
the TCA cycle and glyoxylate shunt during growth on acetate.
Mycobacteria do not inactivate ICD during growth on acetate.
In enterobacteria, the split-ratio of ﬂuxes at the bifurcation of the
oxidative TCA cycle and glyoxylate shunt is maintained by partial
inactivation of ICD, which is reversibly phosphorylated by the
bifunctional kinase-phosphatase AceK8. Although
phosphorylation-mediated inhibition of ICD does not seem to
play a role in mycobacteria (see above), we investigated whether
other mechanisms might contribute to ICD regulation by
measuring total ICD enzyme activity in cells grown on glucose
or acetate as the sole source of carbon and energy. Consistent
with previous studies, we found that total ICD activity in E. coli
cell extracts is threefold lower in acetate-grown cells compared
with glucose-grown cells. In sharp contrast, we found that total
ICD activity in mycobacterial cell extracts is increased rather than
decreased in acetate-grown cells compared with glucose-grown
cells in all of the species that we tested (M. smegmatis, M. bovis
BCG and M. tuberculosis) (Tables 1 and 2). These observations
conﬁrm that mycobacteria do not use phosphorylation-mediated
inhibition of ICD to balance ﬂux partitioning between the TCA
cycle and the glyoxylate shunt.
ICD2 expression is independent of the carbon source. Since
ICD2 seems to be solely responsible for intracellular ICD activity
and carbon ﬂux through the oxidative TCA cycle under standard
growth conditions in vitro, we focused on this isoenzyme to
investigate the mechanism of ﬂux partitioning between the TCA
cycle and the glyoxylate shunt. We found that increased ICD
activity in acetate-grown cells (Table 1) cannot be attributed to
changes in ICD2 protein abundance, which is similar in cells
grown on glucose or acetate (Supplementary Fig. 4). Stable post-
translational modiﬁcations also cannot account for increased ICD
activity in acetate-grown cells, given that ICD speciﬁc activity is
similar in immunoprecipitated fractions from cells grown on
glucose. These results suggest that increased ICD activity in
acetate-grown cells cannot be explained by changes in the
intrinsic activity of ICD2 alone and might involve additional
carbon-responsive elements. ICL is a putative candidate because it
competes with ICD for a shared substrate (isocitrate) and ICL
expression is induced in cells grown on acetate compared with
glucose (Table 3; Supplementary Fig. 4a).
Metabolic cross-activation of ICD by ICL. We used a strain of
M. smegmatis with icl1 transcribed from an anhydrotetracycline
(ATc)-inducible promoter (Supplementary Fig. 5) to demonstrate
that increased expression of ICL1 is accompanied by increased ICD
activity in a dose-dependent manner (Fig. 5a). These results suggest
that ICL1 cross-activates ICD2 in vivo through a direct or indirect
mechanism. We reconstituted this effect in vitro using recombinant
enzymes. Consistent with the in vivo data (Fig. 5a), we found that
rICD2 activity increases in proportion to the amount of rICL1
added to the reaction mix (Fig. 5b). Cross-activation is dependent
on ICL enzymatic activity, because an inactive catalytic-site variant
of ICL1 (rICL1KKAGA) has no rICD2-stimulatory activity in vitro
(Fig. 5b; Supplementary Fig. 6).
These observations suggest that ICL-dependent stimulation of
ICD2 activity might be mediated by metabolic cross-activation
rather than direct protein–protein interaction. Consistent with
this hypothesis, we found that rICD2 activity in vitro is stimulated
by direct addition of glyoxylate to the reaction mix (Fig. 5c),
whereas addition of succinate has no effect (Fig. 5d). Stimulation
of ICD activity by glyoxylate is dose-dependent up to a
concentration of 200 mM, consistent with the intracellular
concentration of glyoxylate that we measured in acetate-grown
cells (B20mM) and about fourfold lower in glucose-grown cells,
which is similar to data from E. coli cultures25. Indeed, these
measurements are likely to underestimate the true concentrations
of intracellular glyoxylate due to the inherent instability and
reactivity of this compound. Moreover, it is likely that glyoxylate
concentrations ﬂuctuate over time and individual cells may
transiently contain higher levels than the measured population
average26–28, consistent with the rheostat-like mechanism of
metabolite-mediated feedback regulation proposed here.
Finally, we employed isothermal titration calorimetry (ITC) to
measure the binding afﬁnity of glyoxylate for MsmICD (Fig. 5e).
Thermodynamic parameters revealed that glyoxylate binds to
MsmICD with high afﬁnity and a stoichiometry of 1:1 (Table 4).
Glyoxylate contributed favourably to the binding entropy
(DS¼ 406 calmol 1), suggesting the presence of conformational
changes. Importantly, MsmICD binding was not detected for
succinate, consistent with the absence of ICD-stimulatory activity
in vitro (Fig. 5f). To investigate the mechanism of glyoxylate-
mediated activation of ICD, we attempted to co-crystallize apo-
MsmICD with glyoxylate but we were unable to resolve glyoxylate
in the resulting crystal structures. Therefore, we used the
MsmICD crystal structure to perform computational docking
studies with glyoxylate to generate models of the MsmICD–
glyoxylate complex structure. The docking studies suggest that
glyoxylate binds close to the active site of MsmICD, making key
interactions with amino acid residues around the catalytic site
(Fig. 5g; Supplementary Fig. 7).
Discussion
Despite the importance of fatty acid catabolism during
M. tuberculosis infection10, the mechanisms that regulate the
partitioning of metabolite ﬂuxes at the bifurcation of the
Table 3 | ICL activity in cell-free extracts of bacteria grown on glucose or acetate.
Bacterial strain ICL activity* Glucose (Glc) ICL activity* Acetate (Ace) Ratio (Glc/Ace)
M. tuberculosis Erdman 0.46±0.15 1.26±0.24 0.37
M. bovis BCG 0.36±0.04 0.84±0.08 0.43
M. smegmatis 0.22±0.03 1.76±0.26 0.13
E. coli 0.01±0.01 0.95±0.68 0.01
Data are means±s.d. (nZ3 independent experiments each performed in triplicate).
*ICL speciﬁc activity in cell-free extracts (U mg 1).
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oxidative TCA cycle and the glyoxylate shunt remain unknown.
Strict regulation of ﬂuxes at this metabolic branch-point is
essential during catabolism of C2-units derived from fatty acids in
order to balance anaplerotic ﬂuxes (glyoxylate shunt) and ﬂuxes
generating energy and biosynthetic precursors (TCA cycle)
(Supplementary Fig. 8). Here, we demonstrate that this balance
is mediated by metabolite-based regulation of ICD2 activity,
whereas imbalancing of branch-point ﬂuxes by overexpression of
ICD1 inhibits growth on acetate (Fig. 6a; Supplementary Table 3).
This growth-inhibitory effect is presumably caused by directing
too much ﬂux into the oxidative TCA cycle at the expense of the
glyoxylate shunt, analogous to E. coli mutants deﬁcient in
phosphorylation-mediated inhibition of ICD29. This inter-
pretation is consistent with limited viable ﬂux combinations of
ICL and ICD on acetate compared with glucose, as modelled by
computational ﬂux-balance analysis using either of these two
substrates as the sole carbon source (Fig. 6b). Loss of ICD activity
not only impairs growth on media with acetate as the sole carbon
source but also leads to the loss of viability over time. These
observations suggest that perturbation of ﬂux partitioning at the
branch-point of the TCA cycle and glyoxylate shunt might
present a potential strategy for chemotherapy. This could be
achieved by modulating the metabolic ﬂuxes to favour the TCA
cycle over the glyoxylate shunt, which would impair anaplerosis
in cells catabolizing fatty acid substrates during infection
in vivo30.
The architecture of the regulatory circuit that controls
bifurcation of ﬂuxes at the branch-point of the TCA cycle and
glyoxylate shunt is strikingly different in mycobacteria compared
with the established regulatory paradigm in E. coli. In E. coli,
branch-point partitioning is controlled by phosphorylation-
mediated inactivation of ICD, which diverts ﬂux away from the
TCA cycle and into the glyoxylate shunt (Fig. 6c)8. In line with
the reported architecture of mycobacterial ICD1 (ref. 31), we ﬁnd
that the 3D architecture of ICD2 appears incompatible with
phosphorylation-mediated control of enzymatic activity. It is
perhaps not surprising, therefore, that all known and putative
AceK proteins exist only in Gram-negative bacteria.
Correspondingly, ICD proteins from the more distantly related
Actinobacteria, including mycobacteria, seem to have lost (or
perhaps never had) these AceK-interacting elements.
Here, we show that branch-point partitioning in mycobacteria
is controlled by metabolite-mediated activation of ICD, which
diverts ﬂux away from the glyoxylate shunt and into the TCA
cycle. Cross-activation of ICD is mediated by glyoxylate, which is
ideally suited for this regulatory role because it is a unique
product of the ICL-catalyzed cleavage of isocitrate to glyoxylate
and succinate. According to this scheme, if glyoxylate levels rise,
the corresponding increase in ICD activity ensures that carbon
ﬂux will shift towards the TCA cycle, leading to a decline in
glyoxylate levels. Conversely, if glyoxylate levels fall, the
corresponding decrease in ICD activity ensures that carbon ﬂux
will shift towards the glyoxylate shunt, leading to a recovery of
glyoxylate levels. Thus, we propose that glyoxylate-mediated
activation of ICD functions as a molecular rheostat to maintain
the proper balance of ﬂuxes between the TCA cycle and the
glyoxylate shunt under steady-state conditions (Fig. 6c). In
computational simulations, a similar partitioning of ﬂuxes
could be achieved by increasing the activity of ICL above a
threshold in E. coli devoid of AceK32, suggesting that ICL can
govern ﬂux partitioning in the absence of phosphorylation-
mediated inactivation of ICD.
Competitive displacement isothermal titration calorimetry
revealed the true potency of glyoxylate, providing a KA of
1.129e5M 1 that is driven by a positive endothermic binding
entropy (DS¼ 406 calmol 1). Computational simulations of
glyoxylate interaction with ICD suggest that the molecule binds
to the enzyme at a site close the catalytic site. Characterization of
this putative allosteric interaction and localization of the binding
site of glyoxylate could provide new opportunities for therapeutic
intervention, as ﬂux partitioning between the TCA cycle and
glyoxylate shunt is critical for survival of M. tuberculosis during
infection. Similar to other NADPþ -dependent ICDs, mycobac-
terial ICD2 forms dimers in solution14,33. According to the
ultrasensitivity theory34, such multimeric structures can mediate
cooperative binding of substrates or allosteric effector molecules,
thus enabling rapid and switch-like responses to environmental
changes35.
The rheostat-like mechanism proposed here involves metabo-
lite-mediated enzyme activation to achieve a balanced bifurcation
of ﬂuxes between two pathways, whereas in E. coli the same ﬂux
balance is achieved by phosphorylation-mediated enzyme inhibi-
tion. In future it will be important to determine whether a
rheostat-like mechanism can be generalized to other bacterial
species in which ICD activity is not repressed during growth on
C2-carbon substrates36–39. Although metabolite-mediated control
has been implicated in metabolic adaptation during switching
between distinct nutritional environments40–42, the results
presented here also demonstrate its importance for metabolic
homoeostasis under conditions of steady-state growth.
Methods
Bacterial strains and culture conditions. E. coli K-12 MG1655 was the reference
wild-type strain used in all E. coli experiments. The DaceK null E. coli strain was
obtained from the Yale E. coli Genetic Stock Center (CGSC#10859). Yellow
ﬂuorescent protein (YFP)-expressing derivatives of both E. coli strains were made
by transformation with a plasmid encoding YFP43. M. tuberculosis Erdman,
M. tuberculosis H37Rv, M. tuberculosis CDC1551, M. tuberculosis HN787, M. bovis
BCG (Pasteur 1173P2), M. smegmatis mc2155 and derivative strains
(Supplementary Table 4) were grown in Middlebrook 7H9 liquid medium (Difco)
supplemented with 0.5% albumin, 0.2% glucose, 0.085% NaCl, 0.5% glycerol and
0.05% tyloxapol. Cultures were grown at 37 C to mid-log phase, corresponding to
optical density at 600 nm (OD600) ofB0.5. Aliquots were stored in 15% glycerol at
 80 C and thawed at room temperature before use; individual aliquots were used
once and discarded. When required, the medium was supplemented with
75 mgml 1 hygromycin (Roche Diagnostics) or 25 mgml 1 kanamycin (Sigma-
K4378). E. coli MG1655 and derivative strains (Supplementary Table 4) were
grown in LB liquid medium (Difco). When required, the medium was
supplemented with 25 mgml 1 kanamycin, 25 mgml 1 chloramphenicol (Sigma-
C0378) or 100 mgml 1 ampicillin (Sigma-A0166).
For growth with single carbon sources, bacteria were cultured in M9 minimal
medium (Difco) supplemented with 2 g l 1 of glucose or acetate, or in deﬁned
medium containing 2.5 g l 1 Na2HPO4, 1 g l 1 KH2PO4, 0.5 g l 1 glutamic acid,
1mg l 1 pyridoxine, 0.5mg l 1 biotin, 15mg l 1 ferric ammonium citrate,
40 g l 1 MgSO4, 0.5mg l 1 CaCl2, 0.6mg l 1 ZnSO4, 0.6mg l 1 CuSO4, 0.8 g l 1
NaCl, 0.5 g l 1 Tyloxapol, and 0.1% fatty acid-free bovine serum albumin (Sigma
A8806) supplemented with 2 g l 1 of glucose or acetate. When required, 0.5 g l 1
of NH4SO4 was added as an alternative nitrogen source in lieu of glutamic acid.
Table 4 | Thermodynamic parameters of glyoxylate binding to MsmICD.
Compound n K (M 1) DH (calmol 1) DS (calmol 1)
Glyoxylate 1.17±0.02 1.10e6±4.21e5 1.129e5±4507 406
Succinate 0.12±12 3.05e3±1.34e4 –8.00e4±8.42e6 –252
Data are representative of three independent experiments with similar results.
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Bacterial growth was monitored by measuring culture OD600 (BioMate5 Fisher
Scientiﬁc) at successive time points. All data for growth kinetics were derived from
at least three independent experiments.
Viability ofM. smegmatis andM. bovis BCG cultures was determined by plating
serially diluted aliquots of cultures on LB solid medium for M. smegmatis or
Middlebrook 7H9 solid medium supplemented with 0.5% glycerol and 10% oleic
acid–albumin–dextrose–catalase (0.5 g l 1 oleic acid, 50 g l 1 bovine serum
albumin fraction V, 20 g l 1 glucose, 40mg l 1 catalase, 8.5 g l 1 NaCl) for
M. bovis BCG. Colony-forming units (CFU) were scored after incubation of plates
at 37 C.
Strain construction. Plasmids and bacterial strains are listed in Supplementary
Table 4. All vectors used for mutant generation, complementation and conditional
gene expression were constructed using TOPO Cloning Technology (Invitrogen).
Unmarked in-frame gene deletions of M. tuberculosis icd1 (rv3339c) and
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Figure 6 | Dysregulation of the ICL/ICD rheostat balance impairs growth on acetate. (a) Growth of wild-type, attB::Pnpicd1 and attB::Phspicd1 strains of
M. bovis BCG in glucose-based (left) or acetate-based (right) minimal medium without glutamate. The attB::Pnpicd1 strain expresses icd1 from the native
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(b) Computationally modelled phase planes of carbon ﬂux between ICD and ICL in glucose-based (left) or acetate-based (right) medium. Heat maps show
scales of predicted growth (maroon, best growth; blue, zero growth) at varying levels of ICD/ICL ﬂux. The dynamic range of ICD ﬂux allowing optimal growth
at each ICL ﬂux value is narrower in acetate-grown cells compared with glucose-grown cells. (c) Bifurcation of metabolic ﬂuxes between the oxidative TCA
cycle and the glyoxylate shunt in E. coli and mycobacteria. In E. coli, the substrate Km of ICL is almost 100-fold higher than the substrate Km of ICD. Partial
inhibition of ICD by AceK-mediated phosphorylation enables partitioning of one-third of the ﬂux into the glyoxylate shunt with the remaining two-thirds of the
ﬂux continuing through the oxidative TCA cycle. In mycobacteria, the substrate Km of ICL1 is only slightly higher than the substrate Km of ICD2. In this context,
glyoxylate-mediated activation of ICD functions as a metabolic rheostat to maintain the optimal partitioning of ﬂuxes between the TCA cycle and the
glyoxylate shunt. ICT, isocitrate; GOX, glyoxylate; a-KG, alpha-ketoglutarate.
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M. smegmatis icd (msm1654), pknG (msm0786), icl1 (msm0911), and icl2
(msm3706) were constructed using a method for two-step homologous recombi-
nation44. The in-frame recombination template was constructed by PCR
ampliﬁcation of E900 bp of the upstream and downstream region of the gene of
interest. Primers were designed to introduce 50 PacI and 30 AvrII sites into the
upstream amplicon including nine bases from the start codon, and 50 AvrII and 30
AscI into the downstream region including nine bases before the stop codon. The
amplicons were veriﬁed by DNA sequencing then restriction digested and ligated
into the PacI and AscI sites of pJG1100, a suicide vector that contains aph
(kanamycin resistance), hyg (hygromycin resistance), and sacB (sucrose sensitivity)
markers45. When inapplicable due to presence of internal restriction sites in the
amplicons, NheI and SpeI were used instead to generate homologous arms.
Disruptions of the M. bovis BCG icd1 (Mb3371c) and icd2 (Mb0067c) genes
were constructed by replacing the chromosomal locus with an interrupted (100 bp)
in-frame icd1::hyg or icd2::hyg allele using a method for one-step homologous
recombination46. Brieﬂy, fragments ofE1 kb ﬂanking the icd1 or icd2 open reading
frame (ORF) were PCR ampliﬁed from M. tuberculosis H37Rv genomic DNA. The
50- and 30- ﬂanking fragments were then cloned into pYUB854 ﬂanking the
hygromycin-resistance gene. A sacB-lacZ cassette excised from pGOAL17 (ref. 47)
was then cloned into the unique PacI site of pYUB854. The ﬁnal plasmids were
ultraviolet-irradiated before electroporation into M. bovis BCG48. Positive clones of
knockout mutants were selected as white colonies on 7H11 agar supplemented with
150mgml 1 hygromycin and 40mgml 1 X-Gal. Replacement of the target gene
with the hygromycin-resistance marker was conﬁrmed by PCR. Primers are listed
in Supplementary Table 5.
Epitope-tagged translational fusions of M. tuberculosis icd1 (rv3339c),
M. tuberculosis icd2 (rv0066c), M. tuberculosis icl1 (rv0467), M. tuberculosis icl2
(rv1916) and M. smegmatis icd (msm1654) were constructed by inserting sequences
encoding the epitopes VSVG, HA, FLAG, Myc or HA into the chromosome
downstream of rv3339c, rv0066c, rv0467, rv1916 or msm1654 (respectively), just
before the stop codon by two-step recombination with the suicide vector pJG1100.
In all cases, the in-frame upstream recombination template was constructed by
PCR ampliﬁcation ofE900 bp of the 30 region of the gene of interest. Primers were
designed analogous to that described for the unmarked gene deletion. The epitope
tags were ampliﬁed with AvrII overhangs and were cloned into the AvrII site at the
junction of the two homologous arms. The resultant plasmids were introduced into
M. smegmatis and M. tuberculosis by electroporation. Transformants (ﬁrst
crossover) were selected on LB agar or 7H10 agar containing 50 mgml 1
hygromycin and 25 mgml 1 kanamycin. Individual colonies were picked and
ampliﬁed in 7H9 liquid medium (no antibiotics) and then plated on LB agar or
7H10 containing 5% sucrose to select for cells in which plasmid excision had
occurred (second crossover). Individual colonies were picked and the replacement
of the gene by the fusion gene or gene deletion was conﬁrmed by PCR. For M.
tuberculosis, cells were plated on 7H10 agar in lieu of LB agar.
For complementation of the M. bovis BCG Dicd1, M. bovis BCG Dicd2 or
M. smegmatis Dicd mutant, the corresponding ORF plus 200 bp of 50-ﬂanking
sequence upstream of the translational start codon was PCR ampliﬁed and ligated
into the attB-integrating promoter-less vector pMV306 digested with XbaI and
HindIII to generate pMV306::Pnpicd1, pMV306::Pnpicd2, or pMV306::Pnpicd,
respectively. Plasmids overexpressing the M. bovis BCG icd1 or icd2 gene were
generated by PCR amplifying the respective ORFs and ligating into the BamHI and
HindIII sites of pMV361 (a pMV306 derivative) downstream of the strong hsp60
promoter to generate pMV306::Phspicd1 and pMV306::Phspicd2. Plasmids were
introduced into M. bovis BCG by electroporation and colonies were selected on
7H11 agar supplemented with 25 mgml 1 kanamycin. Complemented strains were
veriﬁed by PCR.
Growth kinetics. Pre-cultures were inoculated from frozen stocks to an initial
optical density at 600 nm (OD600)E0.05. Cells were grown to early exponential
phase (OD600E0.5), collected by centrifugation (3,000g, 5min), washed three times
with phosphate-buffered saline (PBS) supplemented with 0.05% Tween-80 (Sigma),
resuspended in fresh medium at OD600E0.05, and incubated at 37 C with aera-
tion (180 r.p.m.). At speciﬁed time points, OD600 measurements were made using
an Ultrospec 2000 spectrophotometer (Pharmacia). Where indicated, resuspended
cells were seeded in microtiter plates, sealed with a gas-permeable adhesive seal
(ThermoScientiﬁc, Waltham, USA), and incubated in a BioLector system49,50 for
continuous monitoring of bacterial growth (OD620) and ﬂuorescence.
Time-lapse microscopy. Time-lapse microscopy of E. coli MG1655 (wild-type)
and DaceK strains expressing YFP (Supplementary Table 4) was performed with
minor modiﬁcations51. In brief, bacteria were grown to mid-log phase (OD600
B0.3) in M9 liquid medium containing 2 g l 1 glucose and 2 ml of culture were
spread on a semipermeable membrane, which was then inverted onto a glass
coverslip micro-patterned with rings of SU-8 (65 mm diameter 1.5 mm height)
containing a central post (10 mm diameter 1.5 mm height). The bacteria-free side
of the membrane was overlaid with a PDMS-based microﬂuidic device and the
assembly was clamped between a transparent acrylic cover and base adapter, as
described51. The inlet and outlet ports of the microﬂuidic device were connected to
plastic tubing and bacteria were fed by continuous ﬂow of M9 minimal medium
containing 2 g l 1 glucose or acetate (ﬂow rate, 25 ml min 1). Bacteria were
maintained at 37 C in a microscope-ﬁtted environmental chamber and imaged
using a DeltaVision personalDV microscope (Applied Precision) equipped with a
100 oil-immersion objective. Images were recorded at 5-min intervals on phase-
contrast and ﬂuorescence channels (GFP, excitation ﬁlter 490/20/, emission ﬁlter
528/38) using a CoolSnap HQ2 camera. Images were processed using Softworx
software (Applied Precision) and custom-made macros in ImageJ.
Enzyme assays. ICL activity was measured using the following assay conditions:
25mM imidazole buffer (pH 6.8), 10mM EDTA, 5mM MgCl2, 4mM phenylhy-
drazine and 4mM DL-isocitric acid trisodium salt hydrate. Enzyme assays were
carried out in 96-well plates. Each well contained 100ml of reaction master mix and
100 ml of puriﬁed recombinant protein (0.12 mgml 1). Absorbance readings were
taken at 324 nm using a temperature-controlled (25 C) 96-well plate reader
spectrophotometer (Tecan M200 Pro). ICL speciﬁc activity is deﬁned as
1U¼ 1 mM phenylhydrazone glyoxylate generated per min (mg protein) 1.
ICD activity was measured by monitoring the time-dependent reduction of
NADPþ to NADPH14 using the following assay conditions: 25mM Tris–HCl
pH 7.5, 5mM MgCl2, 100mM NaCl, 8mM NADPþ , and 8mM DL-isocitric acid
trisodium salt hydrate (Sigma). Enzyme assays were carried out in 96-well plates.
Each well contained 100 ml of reaction master mix and 100 ml of puriﬁed
recombinant protein (0.12 mgml 1). Absorbance readings were taken at 340 nm
using a temperature-controlled (25 C) 96-well plate reader spectrophotometer
(Tecan M200 Pro). ICD speciﬁc activity is deﬁned as 1U¼ 1 mM of NADPH
formed per min (mg protein) 1. ICD activity with varying glyoxylate
concentrations was followed at 37 C by ﬂash-freezing the reactions at different
times in 200 ml of acetonitrile. Samples were then prepared for mass spectrometry
analysis to track the production of a-ketoglutarate. Stimulation of ICD activity by
ICL was measured by following NADPH production at 340 nm in the presence of
increasing amounts of recombinant wild-type ICL or mutated (catalytically
inactive) ICL.
Heterologous protein expression. ORFs encoding ICL and ICD were ampliﬁed
by PCR. Amplicons were veriﬁed by DNA sequencing then restriction digested and
ligated into a pET-28a(þ ) vector (Novagen USA) carrying a C-terminal 6-His tag
and a TEV (tobacco etch virus) cleavage site preceding the C-terminal 6-His tag.
The catalytically inactive ICL1KKAGA was synthesized by GenScript, Inc. (Piscat-
away, NJ, USA) and similarly cloned into pET-28a(þ ) (Novagen USA) incor-
porating the C-terminal 6-His tag and TEV cleavage site. The ﬁnal plasmids,
designated pPM010 and pPM011 (catalytically active and catalytically, respec-
tively), were transformed into chemically competent E. coli One Shot BL21 (DE3)
(Invitrogen). Transformed bacteria were grown at 37 C in LB liquid medium to
early log phase (OD600 B0.3). Recombinant protein expression was induced by
addition of 0.2mM IPTG (isopropyl-b-D-thiogalactopyranoside) and bacteria were
cultured at 16 C for 24 h at 180 r.p.m. Cells were harvested by centrifugation
(3,000g, 5min), resuspended in lysis buffer (50mM Tris pH 7.5, 500mM NaCl,
1mM imidazole, 10% glycerol, 1% Tween-20) containing DNase and mini-protease
inhibitor cocktail (Roche), and incubated for 1 h at 4 C. Cells were then disrupted
by 20 cycles of sonication each comprising 15 s of power at 60% amplitude
(Vibracell 75186, Bioblock Scientiﬁc) and 30 s of power off. Cell debris was pelleted
by centrifugation at 30,000g for 30min at 4 C. The clariﬁed supernatant was
incubated with PrepEase resin (His-tagged protein puriﬁcation resin-high speciﬁ-
city) for 12 h at 4 C with gentle agitation (50 r.p.m.) and washed with 50 volumes
of wash buffer (50mM Tris pH 7.5, 500mM NaCl, 5mM imidazole). Proteins were
eluted with 10 volumes of elution buffer (50mM Tris–HCl pH 7.5, 500mM NaCl,
250mM imidazole). The purity of the eluent fractions was checked by SDS–PAGE
and the 6-His tag was removed by cleavage with TEV (Promega). The native
protein was puriﬁed by size-exclusion chromatography on Superdex 75 pg 10/300
GL columns (GE Healthcare). Fractions containing the eluted protein of interest
were analyzed by SDS–PAGE to conﬁrm purity (498%, estimated by Coomassie
Blue staining), concentrated using Vivaspin units (Sartiorius), and stored at
 80 C in buffer containing 50mM Tris–HCl pH 7.5.
Protein extraction and quantiﬁcation. Cells were collected by centrifugation
(3,500g, 15min), and cell pellets were washed with Tris-buffered salineþ 0.02%
tyloxapol, followed by a single wash with Tris-buffered saline alone at 4 C.
Washed cell pellets were resuspended in 50mM Tris–HCl, pH 8.0, 10% glycerol,
1 protease inhibitor (Roche Applied Science), 1 phosphatase inhibitor
(Pierce) and lysed at 4 C in 15 s sonication cycles (Vibracell 75186, Bioblock
Scientiﬁc) at amplitude 60% with 30 s intervals in-between cycles for 5min. Finally,
the cell debris was pelleted at 11,200g, 35min, 4 C and the protein concentration
was estimated with a BCA protein quantiﬁcation kit (ThermoScientiﬁc) with BSA
standards prepared in the same buffer.
Immunoblot analysis. Protein lysates were prepared in the same manner as
described above. Between 50 and 100 mg total protein were separated on NuPAGE
Novex 4–12% bis-Tris gels (Invitrogen) and transferred to nitrocellulose mem-
branes (Bio-Rad, 162-0115, Hercules, CA, USA) for probing using the iBlot system
(Invitrogen). Membranes were incubated in TBS blocking buffer (25mM Tris–HCl
pH 7.5, 150mM NaCl, 0.05% Tween-20) with 5% w/v skim milk powder for 2 h at
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room temperature before incubation with primary antibodies (anti-FLAG (Clone
M2, Sigma); anti-HA (Sigma); anti-Myc (Sigma); anti-VSVG (Clone 16B12,
Sigma); anti-GroEL2, and anti-Ag85) diluted in TBS with 1% BSA overnight. All
antibodies were used at a dilution of 1:1,000 except anti-GroEL2 (1:50,00) and anti-
Ag85 (1:3,000). Membranes were washed ﬁve times in TBS (15min each at room
temperature) before incubating with appropriate secondary antibody for 1 h at
room temperature. Membranes were developed using the colorimetric horseradish
peroxidase substrate 4-chloro-1-naphthol (4CN) (Opit-4CN Kit by Bio-rad).
Antibodies against GroEL2 and Ag85 were generous gifts from Dr J.M. Chen as
part of the National Institutes of Health, National Institute of Allergy and Infec-
tious Diseases, contract HHSN266200400091c entitled ‘Tuberculosis Vaccine
Testing and Research Materials,’ awarded to Colorado State University).
X-ray crystallography. Crystals of M. smegmatis ICD were obtained by vapour
diffusion at 18 C by equilibrating 2 or 4 ml hanging drops containing a 1:1 mixture
of 60mgml 1 protein pre-incubated with 10mM glyoxylate, 10mM MnCl2,
10mM isocitrate, and 10mM NADPþ in crystallization buffer containing 0.1M
Hepes pH 7.5, 0.05 M MgCl2, and 28–34% polyethylene glycol monomethyl ether
550 (Qiagen) over a 500ml reservoir of the same crystallization solution. Crystals
were stabilized by soaking brieﬂy in a cryoprotectant solution (25% w/v glycerol in
crystallization buffer) and ﬂash frozen in liquid nitrogen before data collection.
Diffraction data to 2.8 Å (ICD incubated with glyoxylate, isocitrate, MgCl2 and
NADP) were collected on X06DA of the Swiss Light Source (SLS, PSI, Villigen,
Switzerland). Data were indexed, integrated and scaled with XDS52. Phase
determinations were carried out by molecular replacement using Phaser47 of the
CCP4 Suite, using the published structure of AvICD (PDB: 1ITW) as a template.
Structure ﬁgures were prepared with PyMOL (Molecular Graphics System, Version
1.5.0.1 Schro¨dinger, LLC). Crystallographic statistics are listed in Supplementary
Table 1. Coordinates and structure factors have been deposited in the Protein Data
Bank (PDB accession code PDB: 4ZDA).
Molecular docking. Protein preparation and grid generation. The raw PDB
structure of the ICD was converted into an all atom receptor model, fully prepared
for docking studies, using Protein Preparation Wizard in Maestro (Maestro v.9.8).
Default parameters in the preparation process were used. The protein structural
integrity was checked and missing side chains were built. The protonation and
tautomeric states of the residues were adjusted to match a pH of 7.4. Energy
minimization of the whole structure was performed using an OPLS2005 force ﬁeld.
The docking receptor grid was created using Glide Receptor Grid Generation
(Glide v.9.8). The grid box was centered between the two domains of ICD, in a
region that allowed the grid box to include the whole protein structure. All the
possible binding sites were explored.
Ligand preparation. The initial ligand ﬁle (sdf ﬁle, two-dimensional structure)
was obtained from the Protein Data Bank (PDB). The glyoxylate was prepared for
ligand docking using LigPrep from the Schrodinger suite. Default parameters in the
ligand preparation process were used. A single low energy conformer with proper
bond lengths and angles was generated from the two-dimensional structure. The
protonation state was adjusted to match a pH of 7.4, tautomeric states were
explored, and a ﬁnal minimization step was performed. Glyoxylate was then
docked inside the rigid 3D structure of the protein receptor (ICD), previously
prepared. Glyoxylate was docked in the binding pocket and no other possible poses
were found. An extra precision-docking revealed a binding energy of
 6 kcalmol 1.
Isothermal titration calorimetry (ITC). ITC experiments were conducted on an
automated micro-calorimeter. The experiments were performed at 25 C in ITC
buffer (10mM Tris (pH 7.5), 10mM EDTA, 50mM NaCl2, 2.5mM MgCl2).
Protein concentrations were 15mM for MsmICD, 150mM glyoxylate (determined
by weighing samples on an ultra-microbalance (Mettler Toledo, accurate to
0.001mg). In titration experiments, glyoxylate was injected into a solution of
MsmICD. In the competitive titration experiment, glyoxylate was injected into a
solution of the enzyme. Titrations were carried out with a stirring speed of
750 r.p.m. and 300-s intervals between 4 ml injections. The ﬁrst four injections were
excluded from data ﬁtting because effective mixing in the cell took longer than the
injection intervals. Titrations were run past the point of enzyme saturation to
correct for heats of dilution. The experimental data were ﬁt to a theoretical titration
curve using the Origin software package (version 7.0) provided with the instrument
to afford values of KA (the association constant in M 1), n (stoichiometry of
binding), and DH (the binding enthalpy change in Kcalmol 1). ITC experiments
were performed in duplicate, analyzed independently, and the obtained thermo-
dynamic values were averaged.
Metabolite measurements. Bacteria were grown in Middlebrook 7H9 liquid
medium at 37 C with aeration (180 r.p.m.) to mid-exponential phase, harvested by
centrifugation (3,000g, 5min) washed three times with PBS containing 0.05%
Tween-80 (Sigma), inoculated into Middlebrook 7H9 liquid medium supplemented
with 2 g l 1 glucose or acetate (initial OD600 0.05), and grown at 37 C to mid-log
phase (OD600 B0.5). Samples equivalent to a biomass of 1ml culture at OD600 2
were collected for metabolome analysis by fast ﬁltration and metabolism was
quenched at –20 C in a mixture of acetonitrile:methanol:water (2:2:1), as
described53. Metabolites were measured by LC–MS/MS and direct injection, as
described25,54. Glyoxylate was measured at 12.6±3.3 pmolml 1 of acetate-grown
culture at OD600 1, which corresponds to a biomass of 343.4±17.5 mg. To estimate
the intracellular concentration of glyoxylate in M. smegmatis we used a ratio of
aqueous volume to cellular dry weight of 0.0023 l g 1, as determined for E. coli55.
Data availability. Coordinates and structure factors have been deposited in
the Protein Data Bank (PDB accession code PDB: 4ZDA). All additional data
supporting the ﬁndings presented here are available from the corresponding
authors upon request.
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